Monocytes: A Promising New TRAIL in Ovarian Cancer Cell Therapy-Reference-Cited by-同舟云学术

Monocytes: A Promising New TRAIL in Ovarian Cancer Cell Therapy

Published:2022-11-16 Issue:2 Volume:29 Page:299-301
ISSN:1078-0432
Container-title:Clinical Cancer Research
language:en
Short-container-title:

Author:

Chow Stephanie¹^ORCID,Dorigo Oliver¹^ORCID

Affiliation:

1. 1Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford Cancer Institute, Stanford, California.

Abstract

Summary Adoptive cell transfer of IFN-activated monocytes administered intraperitoneally to patients with platinum-resistant ovarian cancer demonstrated antitumor effects and acceptable tolerability. The exposure of monocytes to IFNα and IFNγ upregulated TRAIL, which triggered caspase 8 and direct cell-to-cell contact-dependent apoptosis of ovarian cancer cells. See related article by Green et al., p. 349

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Oncology

Link

https://aacrjournals.org/clincancerres/article-pdf/doi/10.1158/1078-0432.CCR-22-2877/3225221/ccr-22-2877.pdf

Reference19 articles.

1. Intraperitoneal monocytes plus IFNs as a novel cellular immunotherapy for ovarian cancer: mechanistic characterization and results from a phase I clinical trial;Green;Clin Cancer Res,2023

2. Intraperitoneal recombinant alpha-interferon for "salvage" immunotherapy in stage III epithelial ovarian cancer: a gynecologic oncology group study;Berek;Cancer Res,1985

3. Intraperitoneal chemotherapy with carboplatin and recombinant interferon alpha in ovarian cancer;Ferrari;Eur J Gynaecol Oncol,1994

4. Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire gynecology group randomized phase III study;Hall;Br J Cancer,2004

5. Alpha 2b interferon (IFN) by intraperitoneal administration via temporary catheter in ovarian cancer. Preliminary data;Iaffaioli;Eur J Gynaecol Oncol,1991